FOGHORN THERAPEUTICS INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)

Item 7.01 Regulation FD Disclosure.

On January 9, 2023, Foghorn Therapeutics Inc. (the "Company") issued a press release, a copy of which is furnished as Exhibit 99.1 to this Current Report on Form 8-K. Additionally, the Company is furnishing as Exhibit 99.2 hereto a presentation, dated January 2023, which the Company intends to use in meetings with or presentations to investors.

The information in this Item 7.01 (including Exhibits 99.1 and 99.2 attached hereto) is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.                            Description

  99.1           Press Release issued on     January 9    , 202    3
  99.2           Investor Presentation dated January 2023

© Edgar Online, source Glimpses